Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Key facts
- Who runs it
- Dartmouth-Hitchcock Medical Center
- Where
- Boston, Burlington, and Lebanon, United StatesSee the 4 sites
- Trial code
- Status
- Terminated
- People taking part
- 94 people enrolled
- Started
- 9 Oct 2013
- Ended
- 25 Aug 2025
- Type of study
- Observational
- Record updated
- 15 September 2025
- Why it stopped
- Study was administratively closed by IRB
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Other criteria
- Inclusion/Exclusion Criteria:
- 18 years of age
- Brain tumor(s) to be resected for clinical reasons
- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV
- Adequate tissue available for processing as determined by Pathology
- Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment
- Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy
Where in United States
- Massachusetts General HospitalBoston, United States
- Tufts Medical CenterBoston, United States
- University of VermontBurlington, United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
About the trial
What the trial wants to find out
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas
- Record updated
- 15 September 2025